<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-04-13T02:07:29Z</responseDate><request verb="GetRecord" identifier="oai:www.recercat.cat:11351/12887" metadataPrefix="mets">https://recercat.cat/oai/request</request><GetRecord><record><header><identifier>oai:recercat.cat:11351/12887</identifier><datestamp>2025-05-04T02:55:36Z</datestamp><setSpec>com_2072_378070</setSpec><setSpec>com_2072_378040</setSpec><setSpec>col_2072_378092</setSpec></header><metadata><mets xmlns="http://www.loc.gov/METS/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" ID="&#xa;&#x9;&#x9;&#x9;&#x9;DSpace_ITEM_11351-12887" TYPE="DSpace ITEM" PROFILE="DSpace METS SIP Profile 1.0" xsi:schemaLocation="http://www.loc.gov/METS/ http://www.loc.gov/standards/mets/mets.xsd" OBJID="&#xa;&#x9;&#x9;&#x9;&#x9;hdl:11351/12887">
   <metsHdr CREATEDATE="2026-04-13T04:07:29Z">
      <agent ROLE="CUSTODIAN" TYPE="ORGANIZATION">
         <name>RECERCAT</name>
      </agent>
   </metsHdr>
   <dmdSec ID="DMD_11351_12887">
      <mdWrap MDTYPE="MODS">
         <xmlData xmlns:mods="http://www.loc.gov/mods/v3" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
            <mods:mods xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
               <mods:name>
                  <mods:role>
                     <mods:roleTerm type="text">author</mods:roleTerm>
                  </mods:role>
                  <mods:namePart>Pal, Sumanta</mods:namePart>
               </mods:name>
               <mods:name>
                  <mods:role>
                     <mods:roleTerm type="text">author</mods:roleTerm>
                  </mods:role>
                  <mods:namePart>Kanesvaran, Ravindran</mods:namePart>
               </mods:name>
               <mods:name>
                  <mods:role>
                     <mods:roleTerm type="text">author</mods:roleTerm>
                  </mods:role>
                  <mods:namePart>Molina-Cerrillo, Javier</mods:namePart>
               </mods:name>
               <mods:name>
                  <mods:role>
                     <mods:roleTerm type="text">author</mods:roleTerm>
                  </mods:role>
                  <mods:namePart>Feldman, Darren</mods:namePart>
               </mods:name>
               <mods:name>
                  <mods:role>
                     <mods:roleTerm type="text">author</mods:roleTerm>
                  </mods:role>
                  <mods:namePart>Barata, Pedro</mods:namePart>
               </mods:name>
               <mods:name>
                  <mods:role>
                     <mods:roleTerm type="text">author</mods:roleTerm>
                  </mods:role>
                  <mods:namePart>Powles, Thomas</mods:namePart>
               </mods:name>
               <mods:name>
                  <mods:role>
                     <mods:roleTerm type="text">author</mods:roleTerm>
                  </mods:role>
                  <mods:namePart>Suárez, Cristina</mods:namePart>
               </mods:name>
               <mods:originInfo>
                  <mods:dateIssued encoding="iso8601">2025-04-02T12:56:24Z2025-04-02T12:56:24Z2025-02-26</mods:dateIssued>
               </mods:originInfo>
               <mods:identifier type="none"/>
               <mods:abstract>Immune checkpoint inhibitor; Non-clear cell renal cell carcinoma; Tyrosine kinase inhibitorInhibidor del punt de control immunitari; Carcinoma renal de cèl·lules no clares; Inhibidor de la tirosina cinasaInhibidor del punto de control inmunitario; Carcinoma renal de células no claras; Inhibidor de la tirosina quinasaManagement of advanced non-clear cell renal cell carcinoma (nccRCC) is challenging due to disease rarity and heterogeneity. The combination of multi-targeted tyrosine kinase inhibitor (TKI) with immune checkpoint inhibitor (ICI) has emerged as an effective treatment strategy, but well-designed, phase III randomized clinical trials are needed to demonstrate superiority over current treatment options. Zanzalintinib is a novel, multi-targeted TKI that has demonstrated promising preclinical anti-tumor activity in combination with ICIs. STELLAR-304 is a phase III trial evaluating first-line zanzalintinib plus nivolumab versus sunitinib in advanced nccRCC. Primary endpoints are progression-free survival and objective response rate. Secondary endpoint is overall survival. To our knowledge, STELLAR-304 is the first phase III study assessing a TKI-ICI combination in nccRCC patients across multiple subtypes.STELLAR-304 is sponsored by Exelixis, Inc. (Alameda, CA, USA).</mods:abstract>
               <mods:language>
                  <mods:languageTerm authority="rfc3066"/>
               </mods:language>
               <mods:accessCondition type="useAndReproduction">Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess</mods:accessCondition>
               <mods:subject>
                  <mods:topic>Ronyons - Càncer - Tractament</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>Quimioteràpia combinada</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>Anticossos monoclonals - Ús terapèutic</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>Proteïnes quinases - Inhibidors - Ús terapèutic</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>DISEASES::Neoplasms::Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Urologic Neoplasms::Kidney Neoplasms::Carcinoma, Renal Cell</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Protein Kinase Inhibitors</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>Other subheadings::Other subheadings::Other subheadings::/antagonists &amp; inhibitors</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>Other subheadings::Other subheadings::/therapeutic use</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>DISEASES::Neoplasms::Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Urologic Neoplasms::Kidney Neoplasms::Carcinoma, Renal Cell</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>Other subheadings::Other subheadings::Other subheadings::/drug therapy</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::mecanismos moleculares de acción farmacológica::inhibidores enzimáticos::inhibidores de proteínas cinasas</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>Otros calificadores::Otros calificadores::Otros calificadores::/antagonistas &amp; inhibidores</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>Otros calificadores::Otros calificadores::/uso terapéutico</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>ENFERMEDADES::neoplasias::neoplasias::neoplasias por localización::neoplasias urogenitales::neoplasias urológicas::neoplasias renales::carcinoma de células renales</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia</mods:topic>
               </mods:subject>
               <mods:titleInfo>
                  <mods:title>STELLAR-304: a phase III study of zanzalintinib (XL092) plus nivolumab in advanced non-clear cell renal cell carcinoma</mods:title>
               </mods:titleInfo>
               <mods:genre>info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion</mods:genre>
            </mods:mods>
         </xmlData>
      </mdWrap>
   </dmdSec>
   <structMap LABEL="DSpace Object" TYPE="LOGICAL">
      <div TYPE="DSpace Object Contents" ADMID="DMD_11351_12887"/>
   </structMap>
</mets></metadata></record></GetRecord></OAI-PMH>